Arecor utilizes its proprietary Arestat™ technology platform to enhance existing therapeutic medicines, focusing on improving patient care through safer and more effective treatments. This innovative platform is built on novel insights into the interactions between formulation excipients and proteins, enabling the control of protein behavior under various stress conditions. The application of Arestat™ allows for the development of differentiated products that offer superior kinetics, stable ready-to-administer formulations for intravenous delivery, and concentrated liquid doses suitable for self-administration. Arecor's commitment to innovation is underscored by its extensive intellectual property portfolio, which includes over 50 granted patents and 20 pending applications.

The company is also dedicated to advancing a range of therapeutic areas, particularly in diabetes and chronic conditions, by creating differentiated biosimilars with intellectual property protection. Arecor's technology facilitates various product transformations, such as switching from intravenous to subcutaneous delivery, converting lyophilized powders to liquid formulations, and developing high-concentration antibodies and superior peptides. Additionally, the platform supports the creation of thermostable vaccines and therapeutics, further enhancing the potential for improved patient outcomes and convenience in treatment administration.

United Kingdom

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  

Arecor

Company Details